NKGen Biotech

NKGN · OTC · United States

Share price · NKGN

$0.00-0.05 (-91.67%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NKGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Aug 2026-50.0%
  2. 31 Jul 2026-83.3%
  3. 16 Jun 2026-60.0%
  4. 15 Jun 2026+150.0%
  5. 17 Mar 2026+216.7%
  6. 5 Mar 2026+185.7%
  7. 18 Feb 2026-65.0%
  8. 17 Feb 2026+233.3%
  9. 14 Oct 2025+900.0%
  10. 10 Oct 2025+100.0%

Share of unusual movement by asset

For each asset, the share of NKGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—98%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
NK cell therapyCell therapy
Alzheimer's DiseaseNon-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
March 2028 (1)
TroculeucelPhase 1/2Moderate Alzheimer Disease
Est. primary completion 2028-03 · NCT06189963 · CT.gov ↗
What to watch
April 2028 (1)
TroculeucelPhase 2Alzheimer Disease
Est. primary completion 2028-04 · NCT07228078 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1—$1.9M<$0.1M—-$2.8M operating cash flowreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q3—$2.8M$0.2M—-$3.9M operating cash flowreport ↗
2024-Q2—$3.1M$0.3M$16M-$6.0M operating cash flowreport ↗
2024-Q1—$3.2M$0.3M$5.4M-$4.0M operating cash flowreport ↗
2023-Q3$0$3.9M$9.0M$33M-$14M operating cash flowreport ↗
2023-Q2—$4.0M<$0.1M$1.8M-$0.6M operating cash flowreport ↗
2023-Q1—$3.6M$0.2M—-$0.5M operating cash flowreport ↗
2022-Q3$0$4.1M$0.7M—-$0.5M operating cash flowreport ↗
2022-Q2——$1.3M—-$0.2M operating cash flowreport ↗
2022-Q1——$1.4M—-$0.3M operating cash flowreport ↗
2021-Q3——$1.9M—-$0.1M operating cash flowreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$11M$0.2M$11M-$21M operating cash flowreport ↗

NKGen Biotech reported R&D spend of $10.66M, down 32.0% YoY, cash and equivalents of $0.24M, and a net loss of $44.29M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$0$16M$0.3M$21M-$22M operating cash flowreport ↗
2022-FY$0.1M$17M$0.6M—-$1.6M operating cash flowreport ↗
2021-FY——$1.7M—report ↗

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1 reporting institution held 2.8M shares ($193K, 2.1% of shares outstanding).

#InstitutionSharesValue
1METEORA CAPITAL, LLC2,755,935$193K